Metraipolis › archive › dc_07b540ec113c
Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors — Europe PMC PMID:42104927
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42104927
- DOI
- 10.1093/oncolo/oyag133
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T23:31:05.459Z
- SHA-256 of the archived text
9ca3c693536b6249d8f7f5290e895f2433001c13cb775c96508ec85da3ee91e0- Stable URL of this page
https://metraipolis.com/documento/dc_07b540ec113c
How to cite
Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors — Europe PMC PMID:42104927 — Europe PMC (en), https://europepmc.org/article/MED/42104927 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_07b540ec113c (Metraipolis archive dc_07b540ec113c, sha256 9ca3c693536b6249d8f7f5290e895f2433001c13cb775c96508ec85da3ee91e0)
BibTeX
@misc{dc07b540ec113c,
title = {Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors — Europe PMC PMID:42104927},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42104927},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_07b540ec113c; sha256 9ca3c693536b6249d8f7f5290e895f2433001c13cb775c96508ec85da3ee91e0},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42104927. Agents can read the archived copy with the MCP tool read_document.